Delivering on the Promise of Biosimilars.
Journal
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
ISSN: 1179-190X
Titre abrégé: BioDrugs
Pays: New Zealand
ID NLM: 9705305
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
pubmed:
14
10
2019
medline:
9
4
2020
entrez:
14
10
2019
Statut:
ppublish
Résumé
Fifteen years of experience with biosimilar evaluation in Europe and advancement in the science behind biological medicines, provides a timely moment to open up debate as to whether the requirements for biosimilar approval could be further tailored. Further optimizing of data requirements to truly decisional information will allow to continuously deliver on the promise of biosimilars, providing benefits for patients and society.
Identifiants
pubmed: 31606870
doi: 10.1007/s40259-019-00388-9
pii: 10.1007/s40259-019-00388-9
doi:
Substances chimiques
Biosimilar Pharmaceuticals
0
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM